Certified by Founder Lodge
ARTBIO
United States - Cambridge, Massachusetts
START UP
1 Disclosed Funding Rounds $90,000,000
0 Participating Investments
-
Founded date
2021
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| December, 08 ,2023 | Series A | $90,000,000 |
Third Rock Ventures
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
